| 1 |
Khanna L, Halfdanarson TR, Sonbol MB, Eiring R, Prond T, Camilleri M. Bile Acid Malabsorption in Patients with Neuroendocrine Tumors. Dig Dis Sci 2022;67:2517-25. [PMID: 34365537 DOI: 10.1007/s10620-021-07189-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 2 |
Kulke MH, Kennecke HF, Murali K, Joish VN. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study. Cancer Manag Res 2021;13:7439-46. [PMID: 34611437 DOI: 10.2147/CMAR.S330429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 2021. [PMID: 34378163 DOI: 10.1007/s40273-021-01071-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
|
| 5 |
Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
|
| 6 |
Gordon LG, Elliott TM, Wakelin K, Leyden S, Leyden J, Michael M, Pavlakis N, Mumford J, Segelov E, Wyld DK. The Economic Impact on Australian Patients with Neuroendocrine Tumours. Patient 2020;13:363-73. [PMID: 32072460 DOI: 10.1007/s40271-020-00412-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 7 |
Tchoumba Tchoumi LM, Nchouwet ML, Poualeu Kamani SL, Yousseu Nana W, Douho Djimeli RC, Kamanyi A, Wansi Ngnokam SL. Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar rats. ADV TRADIT MED (ADTM) 2021;21:485-98. [DOI: 10.1007/s13596-020-00470-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 9 |
Benson AB 3rd, Strosberg J, Joish VN, Dharba S, Sapre D, Lapuerta P. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Pancreas 2020;49:408-12. [PMID: 32132510 DOI: 10.1097/MPA.0000000000001496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 10 |
Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 11 |
Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 12 |
Dasari A, Joish VN, Perez-olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Review of Pharmacoeconomics & Outcomes Research 2020;20:507-11. [DOI: 10.1080/14737167.2019.1660646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 13 |
Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20:70. [PMID: 31286272 DOI: 10.1007/s11864-019-0671-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 14 |
Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist 2019;24:1446-52. [PMID: 31189618 DOI: 10.1634/theoncologist.2018-0921] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Ther Adv Endocrinol Metab 2019;10:2042018819828217. [PMID: 30815246 DOI: 10.1177/2042018819828217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 16 |
Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 17 |
Burton T, Lapuerta P. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. Future Oncol. 2018;14:2361-2370. [PMID: 30095284 DOI: 10.2217/fon-2018-0129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 18 |
Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol 2018;14:1155-64. [PMID: 29350062 DOI: 10.2217/fon-2017-0340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Fokam Tagne MA, Noubissi PA, Fankem GO, Kamgang R. Effects of Oxalis barrelieri L. (Oxalidaceae) aqueous extract on diarrhea induced by Shigella dysenteriae type 1 in rats. Health Sci Rep 2018;1:e20. [PMID: 30623055 DOI: 10.1002/hsr2.20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Joish VN, Frech F, Lapuerta P. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clin Ther 2017;39:2338-44. [PMID: 29175096 DOI: 10.1016/j.clinthera.2017.10.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 21 |
Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econ 2018;21:182-8. [PMID: 28959913 DOI: 10.1080/13696998.2017.1387120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 22 |
Hallet J, Law CHL, Cheung M, Mittmann N, Liu N, Fischer HD, Singh S. Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based Analysis. Ann Surg Oncol 2017;24:3312-23. [DOI: 10.1245/s10434-017-5986-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 23 |
Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 2017;28:1569-75. [PMID: 28444114 DOI: 10.1093/annonc/mdx193] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 24 |
Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics 2017;20:945-51. [DOI: 10.1080/13696998.2017.1337019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
